Market Place
Sourcing Support
Skye Bioscience Presenting At Glp-1-Based Therapeutics Summit
07 Apr 2026 //
GLOBENEWSWIRE
Skye Bio Treats First Patient in Higher-Dose Nimacimab Study
02 Apr 2026 //
GLOBENEWSWIRE
Skye Bioscience Reports Q4 FY 2025 Results and Business Update
10 Mar 2026 //
GLOBENEWSWIRE
Skye Bioscience To Reveal 2025 Financials And Business Update
05 Mar 2026 //
GLOBENEWSWIRE
Skye Reports Positive Cbeyond Ph 2A Extension Interim Study
02 Feb 2026 //
GLOBENEWSWIRE
Skye Showcases Peripherally-Restricted CB1 Inhibitor Antibody
29 Jan 2026 //
GLOBENEWSWIRE
Skye Bioscience To Present Poster At Keystone Obesity Conference
21 Jan 2026 //
GLOBENEWSWIRE
Skye Provides 2026 Corporate Outlook
12 Jan 2026 //
GLOBENEWSWIRE
Halozyme & Skye Sign Global ENHANZE Nimacimab Co-Formulated Deal
05 Jan 2026 //
PR NEWSWIRE
Skye Bioscience Releases Q3 2025 Financials And Business Update
10 Nov 2025 //
GLOBENEWSWIRE
Skye Bioscience To Spotlight Rebound Weight Gain Improvement
05 Nov 2025 //
GLOBENEWSWIRE
Skye Bioscience To Unveil Q3 2025 Financials & Business Update
05 Nov 2025 //
GLOBENEWSWIRE
Skye`s CB1 Inhibitor Demonstrates Synergy With Wegovy In Obesity
07 Oct 2025 //
BIOSPACE
Skye Bioscience Reports Ph2a CBeyond Data For Nimacimab Therapy
06 Oct 2025 //
GLOBENEWSWIRE
Skye`s CB1 Blocker Fails To Reduce Weight In Obesity Study
06 Oct 2025 //
FIERCE BIOTECH
Skye Presents Ph 1b Data for Nimacimab at EASD Annual Meeting
19 Sep 2025 //
GLOBENEWSWIRE
Skye Completes 26-week Treatment Phase in Phase 2a CBeyond™ Study
02 Sep 2025 //
GLOBENEWSWIRE
Skye Bio to Host KOL Event on CBeyond Ph2a Topline Data
27 Aug 2025 //
GLOBENEWSWIRE
Skye Bioscience to Join Upcoming Investment, Medical Conferences
21 Aug 2025 //
GLOBENEWSWIRE
Skye Bioscience Reports Q2 2025 Financial Results and Business
07 Aug 2025 //
GLOBENEWSWIRE
Skye Bio`s Q2 2025 Financial Results & Update on Aug 7, 2025
30 Jul 2025 //
GLOBENEWSWIRE
Skye Bioscience Shares Nimacimab Video and Preclinical CB1 Data
23 Jun 2025 //
GLOBENEWSWIRE
Skye Bioscience to Present Preclinical CB1 Antibody Data
17 Jun 2025 //
GLOBENEWSWIRE
Skye Bioscience to Participate in Upcoming Investment Conferences
22 May 2025 //
GLOBENEWSWIRE
Skye Bioscience partners with Arecor to enhance Nimacimab
19 May 2025 //
GLOBENEWSWIRE
Skye Bioscience Reports Q1 2025 Results, Highlights Nimacimab
08 May 2025 //
GLOBENEWSWIRE
Skye Bioscience to Announce 2025 Q1 Financial Results on May 8
07 May 2025 //
GLOBENEWSWIRE
Skye Bioscience to Attend May Investment and Medical Conferences
29 Apr 2025 //
GLOBENEWSWIRE
Skye Bioscience Shows 30% Weight Loss with Nimacimab & Tirzepatide
15 Apr 2025 //
GLOBENEWSWIRE
Skye Bioscience to Announce 2024 Financial Results on March 20th
14 Mar 2025 //
GLOBENEWSWIRE
Skye Bioscience Achieves Weight Loss with CB1-Inhibiting Nimacimab
04 Nov 2024 //
GLOBENEWSWIRE
Skye Bioscience Comments On Monlunabant Phase 2 Results
23 Sep 2024 //
GLOBENEWSWIRE
Skye Bioscience Launches Phase 2 Trial Of Nimacimab For Obesity
22 Aug 2024 //
GLOBENEWSWIRE
Skye Announces Development Plan in Obesity for CB1 Inhibitor, Nimacimab
11 Dec 2023 //
GLOBENEWSWIRE
